Alzamend Neuro, Inc.
ALZN · NASDAQ
10/31/2025 | 7/31/2025 | 4/30/2025 | 1/31/2025 | |
|---|---|---|---|---|
| Valuation | ||||
| PEG Ratio | 0.03 | 0.01 | -0.00 | 0.26 |
| FCF Yield | -13.69% | -49.86% | -19.43% | -2.51% |
| EV / EBITDA | -4.11 | 0.33 | -0.60 | -51.96 |
| Quality | ||||
| ROIC | -22.82% | -50.53% | -28.70% | -30.06% |
| Gross Margin | 0.00% | 0.00% | 0.00% | 0.00% |
| Cash Conversion Ratio | 1.17 | 0.87 | 0.60 | 1.44 |
| Growth | ||||
| Revenue 3-Year CAGR | -100.00% | -100.00% | -100.00% | 423,686.62% |
| Free Cash Flow Growth | 50.42% | -162.91% | 36.87% | 56.99% |
| Safety | ||||
| Net Debt / EBITDA | 4.46 | 2.08 | 3.51 | 3.28 |
| Interest Coverage | 376.79 | -1,087.48 | -2,237.60 | -513.62 |
| Efficiency | ||||
| Inventory Turnover | 0.00 | 0.00 | 0.00 | 0.00 |
| Cash Conversion Cycle | 0.00 | -3,196.60 | -4,503.63 | -5,149.91 |